Taken together, the overall effect is not driven by either change in NTproBNP or HF-related quality-of-life measures, it remains established that potential benefit of sGC modulation might be based on other parameters such as generic quality-of-life measures, which might help explain the benefit regarding HF-related hospitalization. This evidence concerns the gene SGCB and hydrops fetalis.